Crisaborole Ointment Effect on Global Atopic Dermatitis Severity and Early Relief in Pruritus: Pooled Results From Two Phase 3 Clinical Trials

被引：0

作者：

Paller, Amy S. ^{[1
]}

Yosipovitch, Gil ^{[2
]}

Tom, Wynnis L. ^{[3
,4
]}

Lebwohl, Mark ^{[5
]}

Boguniewicz, Mark ^{[6
,7
]}

Call, Robert S. ^{[8
]}

Eichenfield, Lawrence F. ^{[3
,4
]}

Forsha, Douglass W. ^{[9
]}

Rees, William C. ^{[10
]}

Simpson, Eric L. ^{[11
]}

Gold, Linda F. Stein ^{[12
]}

Zaenglein, Andrea L. ^{[13
]}

Tallman, Anna M. ^{[14
]}

Tan, Bill ^{[14
]}

Hebert, Adelaide A. ^{[15
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[2] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

[3] Rady Childrens Hosp San Diego, San Diego, CA USA

[4] Univ Calif San Diego, San Diego, CA 92103 USA

[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[6] Natl Jewish Hlth, Denver, CO USA

[7] Univ Colorado, Sch Med, Denver, CO USA

[8] Clin Res Partners, Richmond, VA USA

[9] Jordan Valley Dermatol & Res Ctr, W Jordan, UT USA

[10] PI Coor Clin Res, Burke, VA USA

[11] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[12] Henry Ford Hlth Syst, Detroit, MI USA

[13] Penn State Univ, Hershey, PA USA

[14] Pfizer Inc, New York, NY USA

[15] Univ Texas Houston, Med Ctr, Houston, TX USA

来源：

PEDIATRICS | 2018年 / 142卷

关键词：

D O I：

10.1542/peds.142.1_MeetingAbstract.815

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

815

引用

页数：2

共 50 条

[21] Crisaborole topical ointment, 2%: A novel, nonsteroidal, topical antiinflammatory, phosphodiesterase 4 inhibitor: Results from two phase 3 studies treating children and adult patients with mild to moderate atopic dermatitis
Paller, Amy
Tom, Wynnis
Lebwohl, Mark M.
Blumenthal, Robin L.
Boguniewicz, Mark
Eichenfield, Lawrence S.
Forsha, Douglass W.
Simpson, Eric L.
Gold, Linda Stein
Zaenglein, Andrea L.
Call, R. S.
Rees, W. C.
Zane, L. T.
Hebert, A. A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB86 - AB86
[22] Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials
Igarashi, Atsuyuki
Tsuji, Gaku
Fukasawa, Shuichi
Murata, Ryusei
Yamane, Satoshi
JOURNAL OF DERMATOLOGY, 2024, 51 (11): : 1404 - 1413
[23] Crisaborole Topical Ointment, 2%, a novel nonsteroidal, anti-inflammatory, topical, phosphodiesterase 4 inhibitor, reduced pruritus and signs of atopic dermatitis in 2 phase 3 studies in children and adults with mild-to-moderate atopic dermatitis
Zane, Lee Thomas
Hebert, Adelaide A.
Eichenfield, Lawrence F.
Lebwohl, Mark G.
Paller, Amy S.
Simpson, Eric L.
Tom, Wynnis L.
Hughes, Matty H.
JOURNAL OF IMMUNOLOGY, 2016, 196
[24] Patient-reported outcomes of ruxolitinib cream for the treatment of atopic dermatitis: Pooled results from two phase 3 studies
Simpson, Eric L.
Augustin, Matthias
Thaci, Diamant
Misery, Laurent
Silverberg, Jonathan I.
Armstrong, April W.
Fuxench, Zelma C. Chiesa
Kuligowski, Michael E.
Venturanza, May E.
Sun, Kang
Papp, Kim
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB178 - AB178
[25] Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials
Eichenfield, Lawrence F.
Boguniewicz, Mark
Simpson, Eric L.
Blauvelt, Andrew
Gooderham, Melinda
Lain, Edward
Chu, David H.
Higham, Robert C.
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II10 - II11
[26] ONCE-DAILY ROFLUMILAST CREAM 0.15% FOR ATOPIC DERMATITIS: POOLED RESULTS: FROM INTEGUMENT-1/2 PHASE 3 TRIALS
Eichenfield, L.
Boguniewicz, M.
Simpson, E.
Blauvelt, A.
Gooderham, M.
Lain, E.
Chu, D.
Higham, R.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S91 - S91
[27] Long-term safety and disease control with Ruxolitinib cream in atopic dermatitis: Pooled results from two phase 3 studies
Papp, K.
Szepietowski, J. C.
Kircik, L.
Toth, D.
Eichenfield, L. F.
Forman, S. B.
Kuligowski, M. E.
Venturanza, M. E.
Ren, H.
Simpson, E. L.
EXPERIMENTAL DERMATOLOGY, 2021, 30 : 43 - 43
[28] Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials
Eric L. Simpson
Dermatology and Therapy, 2017, 7 : 243 - 248
[29] Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials
Simpson, Eric L.
DERMATOLOGY AND THERAPY, 2017, 7 (02) : 243 - 248
[30] Effects of ruxolitinib cream on work productivity and activity impairment in patients with atopic dermatitis: Pooled results from two phase 3 studies
Eichenfield, Lawrence F.
Silverberg, Jonathan I.
Kuligowski, Michael E.
Venturanza, May E.
Sun, Kang
Augustin, Matthias
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB179 - AB179

← 1 2 3 4 5 →